reported that short-term GCs treatment increased the plasma leptin concentration in a dose- and time-dependent manner (31); Plasma leptin levels in patients with Cushing’s syndrome were significantly higher than those in nonobese healthy participants and obese subjects without any metabolic or endocrine illnesses, indicating the role of GCs as a key regulator for leptin synthesis and secretion (32). The gene discussed is LEP; the disease is Cushing syndrome.